The Parkinson’s Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Parkinson’s Disease Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Parkinson’s Disease Market.

Some of the key takeaways from the Parkinson’s Disease Pipeline Report:

• Companies across the globe are diligently working toward developing novel Parkinson’s Disease treatment therapies with a considerable amount of success over the years. 
• Parkinson’s Disease companies working in the treatment market are Neuropore Therapies, Inc., Aspen Neuroscience, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd, Denali Therapeutics, Cerevel Therapeutics, Biogen, Inhibikase Therapeutics, Neuraly, Peptron, Prothena Corporation, Roche, Kissei Pharmaceutical, and others, are developing therapies for the Parkinson’s Disease treatment 

• Emerging Parkinson’s Disease therapies in the different phases of clinical trials are- NPT1220-478, ANPD002, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, KM-819, Prasinezumab, P2B001, DNL 151, Tavapadon, BIIB122, IkT-148009, NLY01, PT320, Prasinezumab, KDT-3594, and others are expected to have a significant impact on the Parkinson’s Disease market in the coming years.   
• In January 2023, The development of a new strategic partnership between Neurocrine Biosciences and Voyager Therapeutics to advance many gene therapies for the treatment of neurological illnesses was announced. A GBA1 gene replacement payload and novel capsids from Voyager’s TRACERTM (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) platform are combined in the preclinical, intravenously administered GBA1 gene therapy programme for Parkinson’s and other GBA1-mediated diseases. Additionally, Voyager and Neurocrine Biosciences have decided to work together on three new gene therapy projects that target uncommon CNS targets and each make use of Voyager’s cutting-edge TRACER capsids.
• In October 2022, Approximately 400 people with Parkinson’s disease and a confirmed pathogenic mutation in the leucine-rich repeat kinase 2 (LRRK2) gene will participate in the global Phase 3 LIGHTHOUSE study to compare the efficacy and safety profile of BIIB122 (DNL151) to placebo. This study is sponsored by Biogen Inc. and Denali Therapeutics Inc
• In September 2022, The two companies established a partnership to create a companion diagnostic for Neuron23’s LRRK2 inhibitor for Parkinson’s disease, which is a precision drug for genetically determined neurological and immunological illnesses. Neuron23 is an early-stage biotechnology business.

Parkinson’s Disease Overview

Parkinson’s disease (PD) is a neurodegenerative condition that primarily affects dopamine-producing (“dopaminergic”)neurons in the substantia nigra, a particular region of the brain.

Get a Free Sample PDF Report to know more about Parkinson’s Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights

Emerging Parkinson’s Disease Drugs Under Different Phases of Clinical Development Include:

• NPT1220-478: Neuropore Therapies, Inc.
• ANPD002: Aspen Neuroscience
• UCB7853: UCB Biopharma
• UB-312: Vaxxinity
• Emrusolmin: Modag
• PT320: Peptron
• KDT-3594: Kissei Pharmaceutical
• KM-819: FAScinate Therapeutics
• Prasinezumab: Hoffmann-La Roche
• P2B001: Pharma Two B Ltd
• DNL 151: Denali Therapeutics
• Tavapadon: Cerevel Therapeutics
• BIIB122: Biogen
• IkT-148009: Inhibikase Therapeutics
• NLY01: Neuraly
• PT320: Peptron
• Prasinezumab: Prothena Corporation/Roche
• KDT-3594: Kissei Pharmaceutical

Route of Administration

Parkinson’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types, such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine 

Parkinson’s Disease Pipeline Therapeutics Assessment

• Parkinson’s Disease Assessment by Product Type
• Parkinson’s Disease By Stage and Product Type
• Parkinson’s Disease Assessment by Route of Administration
• Parkinson’s Disease By Stage and Route of Administration
• Parkinson’s Disease Assessment by Molecule Type
• Parkinson’s Disease by Stage and Molecule Type

DelveInsight’s Parkinson’s Disease Report covers around 150+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Parkinson’s Disease product details are provided in the report. Download the Parkinson’s Disease pipeline report to learn more about the emerging Parkinson’s Disease therapies

Some of the key companies in the Parkinson’s Disease Therapeutics Market include:

Key companies developing therapies for Parkinson’s Disease are – Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., NeuroDerm Ltd., Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Inc., Takeda, Xoc Pharmaceuticals, Sumitomo Pharma Co., Ltd., XWPharma, Athira Pharma, Aptinyx, VistaGen Therapeutics, Inc., 1ST Biotherapeutics, Inc., Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Inc., Alkahest, Inc., Kissei Pharmaceutical Co., Ltd., and others.

Parkinson’s Disease Pipeline Analysis:

The Parkinson’s Disease pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Parkinson’s Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson’s Disease Treatment.
• Parkinson’s Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Parkinson’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Parkinson’s Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Parkinson’s Disease drugs and therapies

Parkinson’s Disease Pipeline Market Drivers

• Increasing prevalence of Parkinson’s Disease patients, robust clinical-stage pipeline are some of the important factors that are fueling the Parkinson’s Disease Market.

Parkinson’s Disease Pipeline Market Barriers

• However, lack of awareness and delayed diagnosis, side effects associated with Parkinson’s disease treatment drugs and other factors are creating obstacles in the Parkinson’s Disease Market growth.

Scope of Parkinson’s Disease Pipeline Drug Insight    

• Coverage: Global
• Key Parkinson’s Disease Companies: Neuropore Therapies, Inc., Aspen Neuroscience, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd, Denali Therapeutics, Cerevel Therapeutics, Biogen, Inhibikase Therapeutics, Neuraly, Peptron, Prothena Corporation, Roche, Kissei Pharmaceutical, and others
• Key Parkinson’s Disease Therapies: NPT1220-478, ANPD002, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, KM-819, Prasinezumab, P2B001, DNL 151, Tavapadon, BIIB122, IkT-148009, NLY01, PT320, Prasinezumab, KDT-3594, and others
• Parkinson’s Disease Therapeutic Assessment: Parkinson’s Disease current marketed and Parkinson’s Disease emerging therapies
• Parkinson’s Disease Market Dynamics: Parkinson’s Disease market drivers and Parkinson’s Disease market barriers 

Request for Sample PDF Report for Parkinson’s Disease Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services